37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival. Glenn Hanna, MD, explains more.
Hi, my name is Glenn Hannah. I'm a medical oncologist in the Center for Head and Neck oncology at Dana Farber Cancer Institute and it is mo Congress 2022. I'm presenting a phase two trial of NovoLOG map for high risk oral Luca play Kia patients with proliferated Luca play Kia. To find a high risk subgroup of disease that has a malignant transformation risk at 10% per year or about 80% of these patients will develop a cancer event Within a five year period, we designed a clinical trial that would give four doses of NovoLOG map immuno therapy to these patients to try to invoke Luca play key a regression, both under the microscope and by size. We were also interested in safety tolerable itty and cancer free and overall survival. We enrolled 33 patients to the study. We saw that 36% of patients had regression in their Luca play Kia's composite score, both sides and histology. We also observed a two year cancer free survival of about 78% in this high risk population. Overall the immune related side effects were manageable at a rate of about 20%. So this is the first study to demonstrate the efficacy of PD one blockade among patients with high risk oral Luca play tia with an acceptable toxicity profile. About a third or more of patients had some evidence of disease regression and we saw favorable to year cancer free survival outcomes. We think immunotherapy as a preventative strategy should be further explored
